Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immatics Teams With MD Anderson On Novel Immuno-Oncology Targets

This article was originally published in Scrip

Executive Summary

Germany's immatics biotechnologies GMBH is establishing a US subsidiary in Houston on the campus of MD Anderson Cancer Center, and the two will work together to produce new cancer immunotherapies derived from immatics' XPRESIDENT technology platform.

You may also be interested in...



Immatics To Go Public Through Merger With ‘Blank Check’ Company Arya

German TCR developer in partnerships with GSK and BMS will go public and receive $252m at closing in a reverse merger-type transaction with Arya.

GSK Partnership With Immatics Seeks TCR Therapeutics For Solid Tumors

Deal Snapshot: GSK obtains rights to two of Immatics’ TCR targets, following on the German firm’s similar deals in recent years with Celgene, Genmab and Amgen.

Deal Watch: J.P. Morgan Brings Continued Brisk Pace Of Transactions

Allergan strikes a pair of deals for gastrointestinal and CNS candidates, while Amgen expands its reach in bispecific antibodies via a partnership with Immatics.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel